Association between BIM polymorphism and lung cancer outcomes: a meta-analysis

Area of Science:

• Oncology
• Genetics
• Pharmacogenomics

Background:

• BIM expression is critical in lung cancer development and patient outcomes following tyrosine kinase inhibitor (TKI) therapy, especially in EGFR-mutant lung cancers.
• A specific BIM polymorphism involves a 2,903-bp deletion in the second exon, the clinical significance of which requires further investigation.

Purpose of the Study:

• To elucidate the association between BIM deletion polymorphism and clinical outcomes in lung cancer patients.
• To evaluate the impact of BIM deletion polymorphism on survival and response to EGFR TKIs.

Main Methods:

• A meta-analysis was conducted, synthesizing data from sixteen cohort studies.
• The analysis included a total of 4393 Wild-Type (WT) and 916 BIM deletion patients.
• Outcomes assessed included progression-free survival (PFS), overall survival (OS), and response rates to EGFR TKIs.

Main Results:

• BIM deletion polymorphism was significantly correlated with shorter PFS and slightly shorter OS compared to the WT group.
• Patients with BIM deletion polymorphism demonstrated significantly inferior responses to EGFR TKIs.
• The findings indicate a negative prognostic impact of BIM deletion in lung cancer patients.

Conclusions:

• Lung cancer patients with the BIM deletion polymorphism exhibit poorer survival and reduced response to TKI therapy.
• The BIM deletion polymorphism serves as a potential prognostic biomarker, particularly for EGFR-mutant lung cancer cohorts.
• Further examination of this biomarker could enhance prognostic assessments in lung cancer management.